文献速递临床生化临床血液与体液

液相色谱串联质谱法测定半乳糖脑苷脂酶活性用于Krabbe病临床诊断

Galactocerebrosidase activity by liquid-chromatography tandem mass spectrometry for clinical diagnosis of Krabbe disease.
PubMed 文献 · Clin Chim Acta · 2021-05-18

该研究开发并临床验证了一种基于液相色谱串联质谱(LC-MS/MS)的白细胞酶学检测方法,用于测定半乳糖脑苷脂酶(GALC)活性以诊断Krabbe病。方法采用商业多重底物和内标,经液液萃取后分析,批内和批间不精密度均小于15%,无基质效应或携带污染,产物检测线性R²为0.99。确诊Krabbe病患者与携带者及非Krabbe个体(正常参考范围)可良好区分。

要点

  • LC-MS/MS法可测定白细胞中痕量残留GALC活性,辅助Krabbe病诊断。
  • 批内和批间不精密度均小于15%,无基质效应或携带污染。
  • ACD抗凝管提供最佳样本稳定性,产物检测线性R²为0.99。

核心结论

  • 开发的LC-MS/MS法可测定白细胞中痕量残留GALC活性,辅助Krabbe病诊断。
  • 多重底物混合物实现内置样本质量控制,并简化多种溶酶体贮积病的评估流程。

研究设计与样本

  • 研究开发并临床验证了使用LC-MS/MS的白细胞酶学检测方法,用于测定GALC活性。
  • 提取的细胞裂解液经定量后与商业多重底物和内标孵育,进行液液萃取,并按临床实验室法规指南评估和验证分析前及分析变异性。

主要发现

  • 酶反应产物通过3.5分钟柱分离与底物分解产物分离。
  • 批内和批间不精密度均小于15%。
  • 未观察到基质效应或携带污染。
  • ACD抗凝管提供最佳样本稳定性。
  • 产物检测呈线性,R²为0.99;在预期疾病范围内可测得GALC活性的微小差异。

关键数值与推荐

  • 批内和批间不精密度均小于15%。
  • 产物检测线性R²为0.99。
  • 酶反应产物通过3.5分钟柱分离与底物分解产物分离。

临床怎么用

  • 该LC-MS/MS法可测量白细胞中痕量残留GALC活性,辅助Krabbe病诊断。
  • ACD抗凝管为最佳样本类型,有助于保证样本稳定性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Deficiency of galactosylcerebrosidase (GALC) causes Krabbe disease. Historically, a diagnosis is made by measuring GALC enzymatic activity with a radioisotope assay. To improve the workflow and performance, we developed and clinically validated a leukocyte enzymatic assay using liquid chromatography tandem mass spectrometry (LC-MS/MS). MATERIALS: Extracted cell lysates were quantified and incubated with commercially available multiplexed substrates and internal standards. Liquid-liquid extraction was performed, and pre-analytical and analytical variability were evaluated and validated following clinical laboratory regulation guidelines. RESULTS: Enzymatic reaction products were resolved from substrate breakdown products by a 3.5-minute column separation. Intra- and inter- assay imprecision were less than 15%. No matrix effects or carryover were observed. ACD anticoagulant tubes provide the best sample stability. Detection of product was linear with an R2 of 0.99. Small differences in GALC activity were measurable near the anticipated disease range. Confirmed cases of Krabbe disease were well differentiated from carriers and non-Krabbe individuals (normal reference range). CONCLUSION: An LC-MS/MS assay was developed, which can measure trace residual GALC activity in leukocytes and aid in the diagnosis of Krabbe disease. The multiplexed mixture allows for built-in sample quality control and enables a streamlined workflow for evaluation of multiple lysosomal storage diseases.

来源:Clin Chim Acta,查看原文。版权归原作者所有。

引用

  1. Liao HC, Jack R, Scott AI, et al. Galactocerebrosidase activity by liquid-chromatography tandem mass spectrometry for clinical diagnosis of Krabbe disease. Clin Chim Acta. 2021. PMID: 34015306. doi:10.1016/j.cca.2021.05.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。